Protalix BioTherapeutics, Inc. PLX
2.72
(0.03)
(1.09%)
as of 25 Sep
- Market cap
- $221.6M
- P/E
- 11.3×
Follow PLX
Insider Buys
alert about insiders buying in the last 12 month
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Older periods | |
|---|---|---|---|---|---|
| 31.23% | 27.27% | (14.44%) | 12.64% |
+8 more TTM periods Free account |
|
| 20.07% | 17.40% | (8.48%) | 7.50% | ||
ROIC |
48.48% | 80.14% | (19.92%) | 16.91% | |
Return on Tangible Assets |
28.58% | 23.91% | (14.66%) | 10.95% | |
Average Days of Receivables |
74.72 | 14.04 | 61.17 | 85.14 | |
Free Cash Flow per Share |
0.10 | 0.16 | (0.17) | (0.15) | |
Free Cash Flow |
7.67 | 13.00 | (13.63) | (11.69) | |
Capital Expenditures |
(2.25) | (2.09) | (1.64) | (1.66) | |
Piotroski F-Score |
6.00 | 6.00 | 2.00 | 5.00 | |
| Other line items | |||||
Cash ROIC |
8.80% | 12.68% | (15.14%) | (12.19%) | |
Accounts Receivable Turnover |
6.21 | 16.60 | 8.98 | 7.44 | |
Accounts Payable Turnover |
0.95 | 0.94 | 1.10 | 1.21 | |
Inventory Turnover |
0.93 | 0.92 | 1.15 | 1.37 | |
Average Days of Payables |
436.92 | 412.97 | 339.86 | 285.61 | |
Days of Inventory on Hand |
474.65 | 484.87 | 347.91 | 295.43 | |
Tax Rate |
(0.19) | (0.20) | 0.18 | (0.17) | |
Research and Development Expense of Revenue |
24.66% | 28.17% | 37.10% | 29.20% | |
Selling, General and Administrative Expense of Revenue |
15.65% | 15.88% | 22.15% | 18.04% | |
Share Based Compensation of Revenue |
2.80% | 3.00% | 4.35% | 3.59% | |
Interest Coverage |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF/Net income |
0.52 | 0.98 | 1.82 | (1.86) | |
Depreciation/Fixed assets |
0.29 | 0.30 | 0.30 | 0.30 | |
Capex/Depreciation |
(1.44) | (1.37) | (1.12) | (1.18) | |
Revenue per Share |
1.01 | 0.96 | 0.67 | 0.78 | |
Operating CF per Share |
0.12 | 0.19 | (0.15) | (0.13) | |
Capex per Share |
(0.03) | (0.03) | (0.02) | (0.02) | |
Capex to Sales |
0.03 | 0.03 | 0.03 | 0.03 | |
Net Profit Margin |
23.50% | 20.07% | (12.52%) | 8.72% |
Columns are period end dates